Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.

Mysler E, Sidiropoulos PI, Balanescu A, Detert J, Xavier RM, Charles-Schoeman C, Bessette L, Crowley A, Kaneko Y, Zhang Z, Nagy O, Liu Y, Ren J, Romero AB, Suboticki JL, DeMasi R, Meerwein S, Fleischmann R, SELECT-SWITCH Study Investigators

Open source

DOI: 10.1016/j.ard.2026.03.013
Published: 2026 Jul
Container: Annals of the rheumatic diseases
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ard.2026.03.013,
  title = {Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.},
  author = {Mysler E and Sidiropoulos PI and Balanescu A and Detert J and Xavier RM and Charles-Schoeman C and Bessette L and Crowley A and Kaneko Y and Zhang Z and Nagy O and Liu Y and Ren J and Romero AB and Suboticki JL and DeMasi R and Meerwein S and Fleischmann R and SELECT-SWITCH Study Investigators},
  year = {2026},
  journal = {Annals of the rheumatic diseases},
  doi = {10.1016/j.ard.2026.03.013},
  url = {https://doi.org/10.1016/j.ard.2026.03.013}
}

RIS

TY  - JOUR
TI  - Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
AU  - Mysler E
AU  - Sidiropoulos PI
AU  - Balanescu A
AU  - Detert J
AU  - Xavier RM
AU  - Charles-Schoeman C
AU  - Bessette L
AU  - Crowley A
AU  - Kaneko Y
AU  - Zhang Z
AU  - Nagy O
AU  - Liu Y
AU  - Ren J
AU  - Romero AB
AU  - Suboticki JL
AU  - DeMasi R
AU  - Meerwein S
AU  - Fleischmann R
AU  - SELECT-SWITCH Study Investigators
PY  - 2026
JO  - Annals of the rheumatic diseases
DO  - 10.1016/j.ard.2026.03.013
UR  - https://doi.org/10.1016/j.ard.2026.03.013
ER  -

APA

E, M., PI, S., A, B., J, D., RM, X., C, C., L, B., A, C., Y, K., Z, Z., O, N., Y, L., J, R., AB, R., JL, S., R, D., S, M., R, F., & Investigators, S. S. (2026). Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.. Annals of the rheumatic diseases. https://doi.org/10.1016/j.ard.2026.03.013

Source records

pubmed · retrieved 2026-09-26T03:47:36.724Z